drugset / Trial / NCT00813774
Bio-availability Comparison of Three Formulations of Certolizumab Pegol in Healthy Volunteers
RandomizedParallel-groupOpen-labelBasic science
Summary
To compare the bioavailability of a single dose of certolizumab pegol solutions given subcutaneously either by one of the three formulations and to investigate safety and tolerability.
Timeline
- Start
- 2008-02
- Primary completion
- 2008-07
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Certolizumab Pegol | Protein / enzyme biologic | 400 mg | Subcutaneous |
Indications
No indication recorded.